China-based CStone Pharmaceuticals (HKG: 2616) and Costa Rica-based drug maker and distributor SteinCares have entered into a licensing agreement. Under the terms of the agreement, SteinCares will obtain exclusive commercialization rights to CStone’s anti-programmed death-ligand 1 (PD-L1) inhibitor sugemalimab (trade name: Cejemly) in the Latin American market, including Brazil, Argentina, Mexico, Chile, Colombia, Costa Rica, Panama, Peru, Guatemala, and Ecuador.
Agreement Details
SteinCares will be responsible for regulatory filing and commercial activities for the drug in the specified territories. CStone will handle the supply of the drug and will receive an undisclosed amount of upfront payment, as well as regulatory filing and sales milestone payments. Additionally, CStone will generate international revenue by selling sugemalimab to SteinCares.
Drug Background
Sugemalimab, developed by CStone using the OmniRat transgenic animal platform, is currently approved in China, the European Union, and the United Kingdom.-Fineline Info & Tech
Leave a Reply